Pilot Study of the Impact of Giant Cell Arteritis and Its Treatment on the Autonomy of the Elderly in the First Year of Care (EPACAPA)

University of Limoges (UL)

Status: Terminated

Conditions: Giant Cell Arteritis in Dependency of Elderly

Treatments: Other: Assessment by questionnaire

Study type: Observational

Funder types: Other

Identifiers

NCT03961113

87RI18_0008 (EPACAPA)

Details and patient eligibility

About

Giant cell arteritis is the leading cause of vasculitis in the elderly. No work evaluates its impact on autonomy. At the diagnosis a gerontological evaluation will be carried out including the scores ADL, iADL, MNA, SF 36, SPPB, FRIED and GDS. A monthly telephone reassessment will collect ADL and iADL. The end-of-study consultation at M12, conducted by a geriatrician, will have the same scores as at M0. This will make it possible to evaluate the difference in the functional autonomy score between M0 and M12 in the elderly with ACG.

Enrollment: 10 patients

Sex: All

Ages: 65+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age greater than or equal to 65 years with at least 2 comorbidities * present, or age greater than or equal to 75 years

• Diagnosis of ACG meeting the diagnostic criteria of ACG 1990 ACR

  • comorbidity = chronic pathology

Exclusion criteria

• Neoplastic pathology under treatment
• Brain pathology with motor disability
• Dementia at a severe stage (MMS <22/30)
• Unable to answer the phone
• Participation in a therapeutic clinical trial

Trial design

10 participants in 1 patient group

assessment by questionnaire

Treatment:

Other: Assessment by questionnaire